Skip to content
Medical Health Aged Care

Novotech Recognized for Excellence in Business Expansion, Innovation, and Marketing at the 2024 Clinical Trials Arena Excellence Awards

Novotech 3 mins read
SYDNEY--BUSINESS WIRE--

Novotech, the global full-service clinical Contract Research Organization (CRO), has received multiple awards in the 2024 Clinical Trials Arena Excellence Awards, recognizing the achievements of our people in Business Expansion, Innovation, and Marketing. These awards highlight our commitment to advancing the clinical trial landscape and delivering specialized solutions across the biotech sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241110857472/en/

2024 Clinical Trials Arena Excellence Award Winner Presented to Novotech (Graphic: Business Wire)

2024 Clinical Trials Arena Excellence Award Winner Presented to Novotech (Graphic: Business Wire)

“We’re grateful for this recognition, which is a direct result of our team’s effort and commitment to our mission,” states Dr. John Moller, CEO, Novotech. “It’s a reminder of what we can accomplish when we work together, and we look forward to continuing this momentum.”

The Clinical Trials Arena Excellence Awards celebrate the pharmaceutical industry’s top achievements, identifying organizations that drive progress and innovation. Novotech’s accolades reflect our proactive strategies, technological advancements, and strong international presence.

Highlights of Novotech’s Award-Winning Strategies:

  • Business Expansion – Novotech has significantly extended our reach through strategic acquisitions, including NCGS, EastHORN, and CBR International. These acquisitions have strengthened our operational capabilities and broadened service offerings, ensuring localized expertise in key biotech hubs. The launch of the Early Phase Strategic Delivery Unit (EP SDU) enhances trial support for biotech companies by leveraging Australia and New Zealand’s clinical excellence and regulatory efficiencies.
  • Innovation in Data-Driven Trials – Novotech’s innovation award reflects its adoption of advanced technologies, including AI and big data analytics, which streamline trial design and execution. Partnerships with Medidata and ObvioHealth have strengthened our capacity for virtual trials and predictive analytics, leading to better site selection, faster patient recruitment, and improved trial outcomes.
  • Strategic Marketing Leadership – Under the direction of Toyna Chin, Global Director of Marketing, Novotech’s rebranding has elevated the company’s brand position as a global CRO leader. Strategic, multi-channel campaigns have increased brand recognition and positioned Novotech as a trusted partner, particularly within the US and European markets.

“I am deeply honored to accept this recognition, but it truly reflects the remarkable dedication and talent of our entire marketing organization. Their relentless effort and collaboration are what make our success possible. This award is a tribute to the passion and unity that drives us forward, proving that true marketing excellence is always the result of a collective vision and shared purpose.” - Toyna Chin, Global Director of Marketing, Novotech

About Novotech Novotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena Excellence Awards 2024, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-CRO.com


Contact details:

Media Contact
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135

Media

More from this category

  • Medical Health Aged Care
  • 14/01/2025
  • 00:26
King Faisal Specialist Hospital & Research Centre

KFSHRC Modernizes Biobank Center… Ushering an Era of Personalized Medicine

RIYADH, Saudia Arabia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Center (KFSHRC) has announced the modernization of its Biobank Center, marking a significant milestone in healthcare and medical research within the Kingdom. This modernization aligns with the healthcare goals of Saudi Vision 2030, which emphasize prevention, public health, innovation, and the long-term sustainability of medical research. The Biobank Center aims to accelerate advancements in personalized medicine, improve patient outcomes, and foster novel research and academic excellence.Dr. Björn Zoëga, Deputy CEO of KFSHRC, stated: "The modernization of the KFSHRC Biobank reflects our commitment to medical innovation…

  • Medical Health Aged Care
  • 13/01/2025
  • 11:40
Heart Research Australia

Healthy Heart, Sharp Mind: The Link Between Heart Health and Ageing Well

This February is REDFEB, Heart Research Australia’s heart awareness month, dedicated to raising awareness about heart disease and encouraging Australians to wear red and donate to fund vital research. Millions of Australians are at risk of heart disease, but fewer realise that keeping their heart healthy can also help protect their brain, memory, and cognitive function, reducing the risk of conditions like dementia as they age. With cardiovascular disease affecting more than 4 million Australians and remaining the leading cause of death, it’s not just your heart at stake — your brain health depends on it too. The Heart-Brain Connection“Heart…

  • Medical Health Aged Care
  • 13/01/2025
  • 06:15
Royal Australian College of GPs

Cleanbill report more evidence Medicare needs significant investment: RACGP

Cleanbill’s 2025 Blue Report highlights the need for an urgent injection of funding in Medicare to support more bulk billing and reduce out-of-pocket costs, says the Royal Australian College of GPs (RACGP). While the latest Medicare data shows 77.6% of GP consults are bulk billed, Cleanbill’s independent report, released today shows the percentage of practices bulk billing new adult patients without concession cards continued to fall, to 21%. However, this decline slowed after the Government tripled bulk billing incentives, showing the value of this investment. The Report also shows average out-of-pocket costs increased 4.1% to $43.38. RACGP President Dr Michael…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.